Abstract:Sporadic Alzheimer disease (AD) is related to advancing age far more than to any other risk factor and ultimately affects almost half of the population over age 85. Despite its remarkable prevalence among the elderly, it has been regarded as a specific disease, distinct from "normal aging." This view is supported in large part by clinical and pathologic similarities to early-onset, dominantly inherited familial AD, where genetic mutations related to beta-amyloid have been identified. There is much evidence that sporadic AD overlaps with normal aging in many clinical and pathologic features. Some of the many molecular age-related changes (ARCs) affecting the brain, both intrinsic (programmed) and extrinsic (stochastic), are reviewed, with discussion of the effects they have singly and collectively on neuronal viability and vulnerability. The effect of ARCs on the brain is seen as the biologic manifestation of increasing entropy, an approach that helps to explain the progressive decline of neural and cognitive function over time; the ability of multiple, varied ARCs to summate as individuals age; the transitional relationship between normal aging, mild cognitive impairment, and AD; and the apparent differences between normal aging and AD. Increasing entropy, manifest through a complex network of interacting ARCs, is seen as the fundamental driving cause of neural and cognitive decline in the elderly, as well as the overriding etiologic principle in further transition to sporadic AD. Research on sporadic AD has largely focused on finding a single causal metabolic disorder or genetic mutation. Multiple ARCs contribute to declining function and increased frailty in the aging brain, however, and to the catastrophic disintegration of sporadic AD. Effective prevention or treatment will depend on recognizing the contributions of a multiplicity of ARCs to AD and reducing the burden of as many as possible. The role of amyloid is seen as one element in the larger network of senescent changes involving the aging brain.

Aging and Alzheimer's Disease: Comparison and Associations from Molecular to System Level.

Aging and Alzheimer’s disease: Comparison and associations from molecular to system level

Progress in molecular mechanisms of β-amyloid peptides in alzheimer's disease

The Relationship Between Brain Aging and Preclinical Alzheimer′s Disease

Aging of the brain, entropy, and Alzheimer disease

Alzheimer's disease: insights into pathology, molecular mechanisms, and therapy.

Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer’s disease

New Insights Into the Pathogenesis of Alzheimer's Disease

Aging as a target for the prevention and treatment of Alzheimer's disease

Sequence of Molecular Events in the Development of Alzheimer's Disease: Cascade Interactions from Beta-Amyloid to Other Involved Proteins

Alzheimer’s Disease and Vascular Aging

Pathogenesis, Animal Models, and Drug Discovery of Alzheimer’s Disease

The Late Stage of Abnormal Aging: Dementia

Progress in the Study of the Correlation Between Cerebral Amyloid Angiopathy and Alzheimer's Disease

Molecular Mechanisms of Neuroinflammation in Aging and Alzheimer’s Disease Progression

DNA Damage Accumulation in Aging Brain and Its Links to Alzheimer’s Disease Progression

Changes in the Extracellular Matrix with Aging: A Larger Role in Alzheimer's Disease

Neurobiological Mechanisms of Cognitive Decline Correlated with Brain Aging

Membrane Aging As the Real Culprit of Alzheimer’s Disease: Modification of a Hypothesis

Associations of Anxiety with Amyloid, Tau, and Neurodegeneration in Older Adults Without Dementia: A Longitudinal Study.

The dopaminergic system and Alzheimer's disease